<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372928</url>
  </required_header>
  <id_info>
    <org_study_id>17-32HC</org_study_id>
    <nct_id>NCT03372928</nct_id>
  </id_info>
  <brief_title>Essential Amino Acids and Protein Kinetics During Caloric Deprivation</brief_title>
  <official_title>The Effects of Varying Essential Amino Acid Intakes on Resting and Post-exercise Skeletal Muscle and Whole-body Protein Kinetics During Negative Energy Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Army Research Institute of Environmental Medicine</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Michigan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United States Army Research Institute of Environmental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The amount of essential amino acids (EAA) necessary to maximally stimulate muscle protein&#xD;
      synthesis and optimize whole-body net protein balance during caloric deprivation has not been&#xD;
      determined. This study will address that gap in knowledge by examining the resting and&#xD;
      post-exercise muscle and whole-body protein kinetic responses to ingesting varying amounts of&#xD;
      EAA after a 5 day period of negative energy balance. This study will provide the initial&#xD;
      evidence to support the development of a recovery-based food product for military combat&#xD;
      rations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Short-term negative energy balance downregulates muscle protein synthesis and upregulates&#xD;
      whole-body proteolysis and amino acid (AA) oxidation, thereby increasing nitrogen excretion&#xD;
      and exacerbating whole-body and skeletal muscle protein loss. Consumption of quality proteins&#xD;
      high in essential amino acid (EAA) content may attenuate protein loss during energy deficit&#xD;
      by restoring whole-body and skeletal muscle anabolic potential to that observed in a&#xD;
      eucaloric state. During energy balance, muscle protein synthesis appears to be maximally&#xD;
      stimulated after consuming 15 g of EAA at rest and after conventional resistance-type&#xD;
      exercise. In response to a short-term energy deficit that downregulated basal muscle protein&#xD;
      synthesis by as much as 27%, consuming 15 g (~7.5 g EAA) and 30 g (~15 g EAA) of whey protein&#xD;
      after a bout of resistance exercise restored muscle protein synthesis rates to resting,&#xD;
      fasted rates observed in the eucaloric state in a dose dependent manner. The effect of EAA&#xD;
      intakes above 15 g on resting and post-exercise muscle protein synthesis and the whole-body&#xD;
      protein anabolic response during acute energy deficit has not been determined. This study&#xD;
      will assess resting and post-resistance exercise whole-body and skeletal muscle protein&#xD;
      synthesis responses to across a spectrum of EAA intakes following a well-controlled,&#xD;
      short-term (5-d) energy deficit (30% energy deficit). Using a randomized, double-blind,&#xD;
      cross-over design, 20 resistance trained (≥ 2 d/wk for the past 6 mo) adults will undergo&#xD;
      two, non-consecutive 5-d energy deficit periods, separated by a 14-d washout period. Resting&#xD;
      and post-resistance exercise (single leg exercise model) whole-body protein turnover and&#xD;
      skeletal muscle protein synthesis responses to two different doses of EAA (standard, 0.10&#xD;
      g/kg vs high, 0.30 g/kg) will be determined the morning after completing the 5-d energy&#xD;
      deficit. This design will test the hypothesis that higher absolute doses of EAA are required&#xD;
      to maintain resting and post-exercise anabolic responses during energy deficit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, cross-over controlled trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial, Resting Muscle Protein Synthesis Rates</measure>
    <time_frame>3 hour measure of muscle protein synthesis</time_frame>
    <description>Assessed using stable isotope infusions of phenylalanine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial, Post-exercise Muscle Protein Synthesis Rates</measure>
    <time_frame>3 hour measure of muscle protein synthesis</time_frame>
    <description>Assess using stable isotope infusions of phenylalanine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>How Well Participants Suppress the Degradation of Body Proteins While Stimulating the Growth of New Proteins After Ingesting Varying Doses of EAA at Rest and After Exercise. Net Whole-body Protein Balance</measure>
    <time_frame>3 hour measure of whole-body protein balance</time_frame>
    <description>Assessed using stable isotope infusions of tyrosine. Net Whole-body Protein Balance is defined as whole-body protein synthesis - whole-body protein breakdown)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Muscle Protein Synthesis</condition>
  <condition>Whole-body Protein Balance</condition>
  <arm_group>
    <arm_group_label>Standard EAA Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EAA dose provided at 0.10 g/kg body mass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High EAA Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EAA dose provided at 0.30 g/kg body mass</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard EAA</intervention_name>
    <description>EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation</description>
    <arm_group_label>Standard EAA Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High EAA</intervention_name>
    <description>EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation</description>
    <arm_group_label>High EAA Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 - 35 years&#xD;
&#xD;
          -  Body mass index &lt; 30.0 kg/m2&#xD;
&#xD;
          -  Healthy without evidence of chronic illness or musculoskeletal injury as determined by&#xD;
             the USARIEM Office of Medical Support and Oversight (OMSO)&#xD;
&#xD;
          -  Resistance exercise trained defined by self-report as performing ≥ 2 sessions/wk for&#xD;
             previous 6 mo&#xD;
&#xD;
          -  Refrain from taking any nonsteroidal anti-inflammatory drugs (e.g., aspirin, Advil®,&#xD;
             Aleve®, Naprosyn®), or any other aspirin-containing product for 10 days before&#xD;
             starting and at least 5 days after completing the study&#xD;
&#xD;
          -  Willing to refrain from alcohol, smoking any nicotine product (includes e-cigarettes);&#xD;
             vaping, chewing tobacco, caffeine, and dietary supplement use throughout the entire&#xD;
             study period&#xD;
&#xD;
          -  Supervisor approval for federal civilian employees and non-HRV active duty military&#xD;
             personnel working within the US Army Natick Soldier Systems Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Musculoskeletal injuries that compromise exercise capability as determined by the&#xD;
             USARIEM Office of Medical Support and Oversight (OMSO)&#xD;
&#xD;
          -  Metabolic or cardiovascular abnormalities, gastrointestinal disorders (e.g., kidney&#xD;
             disease, diabetes, cardiovascular disease, etc.)&#xD;
&#xD;
          -  Abnormal PT/PTT test or problems with blood clotting&#xD;
&#xD;
          -  History of complications with lidocaine&#xD;
&#xD;
          -  Present condition of alcoholism, anabolic steroids, or other substance abuse issues&#xD;
&#xD;
          -  Blood donation within 8-wk of beginning the study&#xD;
&#xD;
          -  Pregnancy (self-report or results of urine pregnancy test before body composition&#xD;
             testing)&#xD;
&#xD;
          -  Unwillingness or inability to consume study diets or foods provided&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan M Pasiakos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Military Nutrition Division, USARIEM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Army Research Institute of Environmental Medicine</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <results_first_submitted>April 20, 2020</results_first_submitted>
  <results_first_submitted_qc>October 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03372928/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03372928/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a cross-over design study. 19 volunteers completed both the standard and high EAA testing phases.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low EAA First, Then High EAA</title>
          <description>Participants received EAA provided relative to body mass at a standard dose (0.10 g/kg; LOW)) during energy deprivation first, then received EAA provided relative to body mass at a high dose (0.3 g/kg; HIGH) during energy deprivation.</description>
        </group>
        <group group_id="P2">
          <title>High EAA First, Then Low EAA</title>
          <description>Participants received EAA provided relative to body mass at a high dose (0.30 g/kg; HIGH) during energy deprivation first, then received EAA provided relative to body mass at a low dose (0.1 g/kg; LOW) during energy deprivation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (5 d Energy Deficit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (14 d)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (5 d Energy Deficit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants were randomized to receive all interventions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilograms per meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postprandial, Resting Muscle Protein Synthesis Rates</title>
        <description>Assessed using stable isotope infusions of phenylalanine.</description>
        <time_frame>3 hour measure of muscle protein synthesis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard EAA Dose</title>
            <description>EAA dose provided at 0.10 g/kg body mass&#xD;
Standard EAA: EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation</description>
          </group>
          <group group_id="O2">
            <title>High EAA Dose</title>
            <description>EAA dose provided at 0.30 g/kg body mass&#xD;
High EAA: EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial, Resting Muscle Protein Synthesis Rates</title>
          <description>Assessed using stable isotope infusions of phenylalanine.</description>
          <units>percent per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.01"/>
                    <measurement group_id="O2" value="0.061" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postprandial, Post-exercise Muscle Protein Synthesis Rates</title>
        <description>Assess using stable isotope infusions of phenylalanine.</description>
        <time_frame>3 hour measure of muscle protein synthesis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard EAA</title>
            <description>Arm:&#xD;
EAA dose provided at 0.10 g/kg body mass&#xD;
Standard EAA: EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation</description>
          </group>
          <group group_id="O2">
            <title>High EAA</title>
            <description>Arm:&#xD;
EAA dose provided at 0.30 g/kg body mass&#xD;
High EAA: EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial, Post-exercise Muscle Protein Synthesis Rates</title>
          <description>Assess using stable isotope infusions of phenylalanine.</description>
          <units>percent per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.01"/>
                    <measurement group_id="O2" value="0.065" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>How Well Participants Suppress the Degradation of Body Proteins While Stimulating the Growth of New Proteins After Ingesting Varying Doses of EAA at Rest and After Exercise. Net Whole-body Protein Balance</title>
        <description>Assessed using stable isotope infusions of tyrosine. Net Whole-body Protein Balance is defined as whole-body protein synthesis - whole-body protein breakdown)</description>
        <time_frame>3 hour measure of whole-body protein balance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard EAA</title>
            <description>Arm:&#xD;
EAA dose provided at 0.10 g/kg body mass&#xD;
Low EAA: EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation</description>
          </group>
          <group group_id="O2">
            <title>High EAA</title>
            <description>Arm:&#xD;
EAA dose provided at 0.30 g/kg body mass&#xD;
High EAA: EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation</description>
          </group>
        </group_list>
        <measure>
          <title>How Well Participants Suppress the Degradation of Body Proteins While Stimulating the Growth of New Proteins After Ingesting Varying Doses of EAA at Rest and After Exercise. Net Whole-body Protein Balance</title>
          <description>Assessed using stable isotope infusions of tyrosine. Net Whole-body Protein Balance is defined as whole-body protein synthesis - whole-body protein breakdown)</description>
          <units>grams of protein per 180min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.7"/>
                    <measurement group_id="O2" value="21.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <desc>non-serious adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>Low EAA First, Then High EAA: Low EAA Treatment</title>
          <description>EAA dose provided at 0.10 g/kg body mass during first intervention, then EAA dose provided at 0.30 g/kg body mass during second intervention.&#xD;
Low EAA Treatment Period</description>
        </group>
        <group group_id="E2">
          <title>High EAA First, Then Low EAA: Low EAA Treatment</title>
          <description>EAA dose provided at 0.30 g/kg body mass during first intervention, then EAA dose provided at 0.10 g/kg body mass during second intervention.&#xD;
Low EAA Treatment Period</description>
        </group>
        <group group_id="E3">
          <title>Low EAA First, Then High EAA: High EAA Treatment</title>
          <description>EAA dose provided at 0.10 g/kg body mass during first intervention, then EAA dose provided at 0.30 g/kg body mass during second intervention.&#xD;
High EAA Treatment Period</description>
        </group>
        <group group_id="E4">
          <title>High EAA First, Then Low EAA: High EAA Treatment</title>
          <description>EAA dose provided at 0.30 g/kg body mass during first intervention, then EAA dose provided at 0.10 g/kg body mass during second intervention.&#xD;
High EAA Treatment Period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mild erythema</sub_title>
                <description>Non-serious adverse event, very mild erythema. No cellulitis or e/o abscess. No significant pain or tenderness. Diagnosis: contact dermitits.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jess Gwin</name_or_title>
      <organization>US Army Research Institute of Environmental Medicine</organization>
      <phone>508-206-2300</phone>
      <email>jessica.a.gwin.ctr@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

